Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Approval Alert | Treosulfan/Fludarabine Injection for HSCT Conditioning in AML/MDS
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
